SCHEMBL2660078

SCHEMBL2660078

O=C(NCc1nnn[nH]1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.47
HDAC6 Q9UBN7 3/20 0.46
HPGD P15428 3/20 0.46
ALDH1A1 P00352 2/20 0.46
HDAC1 Q13547 2/20 0.46
MAPK10 P53779 1/20 0.45
ERCC1 P07992 1/20 0.44
ERCC4 Q92889 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
ADORA1 P30542 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.42
ROCK2 O75116 1/20 0.42
RPS6KA5 O75582 1/20 0.42
MAP4K4 O95819 1/20 0.42
PRKCG P05129 1/20 0.42
PRKACA P17612 1/20 0.42
RPS6KB1 P23443 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6220076 0.85 RAB9A (0.49) GAASMN1; SMN2HDAC6ALDH1A1HDAC2
SCHEMBL20785197 0.85 ALDH1A1 (0.47) GAASMN1; SMN2HPGDALDH1A1KDM4E
SCHEMBL13760113 0.82 PLK1 (0.47) SMN1; SMN2HDAC6ALDH1A1HDAC1MAPT
SCHEMBL23236676 0.81 RAB9A (0.53) SMN1; SMN2HPGDALDH1A1HDAC1KDM4E
SCHEMBL3120859 0.78 CYP1A2 (0.32)
SCHEMBL16742500 0.77 CYP1A2 (0.53) GAAHDAC6HPGDALDH1A1HDAC1
SCHEMBL16921897 0.74 NPC1 (0.47) HPGDALDH1A1ROCK2ROCK1KMT2A
SCHEMBL18939456 0.74 GAA (0.57) GAASMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL15315287 0.74 HTT (0.44) GAASMN1; SMN2HDAC6HPGDALDH1A1
SCHEMBL8044468 0.73 TDP1 (0.46) GAASMN1; SMN2HDAC6HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957068-A2 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES Eli Lilly & Company (US) 2008-08-20 EP claimed
WO-2007120270-A2 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-10-25 WO claimed
WO-2015161011-A1 BENZAMIDE CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-10-22 WO disclosed
EP-1957068-A2 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES Eli Lilly & Company (US) 2008-08-20 EP disclosed
WO-2007120270-A2 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-10-25 WO disclosed
EP-0562734-B1 Anti-tumour compounds containing quinazoline and tetrazole rings ZENECA LTD (GB) 1995-12-20 EP disclosed